S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
What is the Penalty for Excess Contributions to an IRA?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
What is the Penalty for Excess Contributions to an IRA?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
What is the Penalty for Excess Contributions to an IRA?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
What is the Penalty for Excess Contributions to an IRA?
NASDAQ:IMMP

Immutep (IMMP) Stock Forecast, Price & News

$2.01
0.00 (0.00%)
(As of 06/1/2023 ET)
Compare
Today's Range
$2.01
▼
$2.01
50-Day Range
$1.54
▼
$2.62
52-Week Range
$1.47
▼
$3.90
Volume
N/A
Average Volume
985,869 shs
Market Capitalization
$176.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Immutep MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
397.5% Upside
$10.00 Price Target
Short Interest
Healthy
0.89% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Immutep in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.38) to ($0.49) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.23 out of 5 stars

Medical Sector

1801st out of 1,980 stocks

Pharmaceutical Preparations Industry

903rd out of 978 stocks

See Top Rated MarketRank™ Stocks Here

IMMP stock logo

About Immutep (NASDAQ:IMMP) Stock

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Receive IMMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immutep and its competitors with MarketBeat's FREE daily newsletter.

IMMP Stock News Headlines

May 29, 2023 | americanbankingnews.com
Comparing Immutep (NASDAQ:IMMP) & Vaccitech (NASDAQ:VACC)
May 21, 2023 | americanbankingnews.com
Maxim Group Boosts Immutep (NASDAQ:IMMP) Price Target to $10.00
June 2, 2023 | Vantage Point (Ad)
Having Trouble in Your Trading?
If you’re having issues in your trading, it could be that it's not you - it really is the market… Well, you’re in control. You can sit on the sideline when it feels right or anticipate massive trend reversals with A.I. like I’ll show you in this upcoming FREE Live A.I. Stock Market Training.
May 18, 2023 | msn.com
Maxim Group Maintains Buy Rating for Immutep: Here's What You Need To Know
May 18, 2023 | finance.yahoo.com
Immutep (IMMP) Surges 65% on Upbeat Lung Cancer Study Data
May 17, 2023 | msn.com
Immutep Soars with New Cancer Treatment
May 17, 2023 | msn.com
Immutep Shares Spike As Cancer Tratement Shows Favorable Results In Phase 2 Trial
May 16, 2023 | finance.yahoo.com
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer
June 2, 2023 | Vantage Point (Ad)
Having Trouble in Your Trading?
If you’re having issues in your trading, it could be that it's not you - it really is the market… Well, you’re in control. You can sit on the sideline when it feels right or anticipate massive trend reversals with A.I. like I’ll show you in this upcoming FREE Live A.I. Stock Market Training.
May 12, 2023 | americanbankingnews.com
Immutep (NASDAQ:IMMP) Stock Crosses Below 50 Day Moving Average of $1.67
May 2, 2023 | finance.yahoo.com
Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma
April 26, 2023 | finance.yahoo.com
Immutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meeting
April 20, 2023 | americanbankingnews.com
Immutep (NASDAQ:IMMP) Stock Price Crosses Below 50 Day Moving Average of $1.71
November 10, 2022 | finance.yahoo.com
Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022
November 9, 2022 | finance.yahoo.com
Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination
November 4, 2022 | finance.yahoo.com
Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference
October 7, 2022 | globenewswire.com
Immutep Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting - GlobeNewswire
October 7, 2022 | marketscreener.com
Immutep Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 2022 Annual Meeting - Marketscreener.com
October 4, 2022 | marketscreener.com
Immutep Says US FDA Awarded Fast Track Designation for Proposed Treatment of First-Line Non-Small Cell Lung Cancer - Marketscreener.com
October 4, 2022 | seekingalpha.com
Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype - Seeking Alpha
October 4, 2022 | globenewswire.com
Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer - GlobeNewswire
October 4, 2022 | finance.yahoo.com
Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer
October 4, 2022 | marketscreener.com
Wilsons Equity Research - Immutep Limited (IMM) | FastTrack for Efti in 1st line NSCLC (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey) - Marketscreener.com
October 4, 2022 | marketscreener.com
Immutep Gains US FDA Fast Track Designation for Immunotherapy Drug; Shares Jump 8% - Marketscreener.com
September 26, 2022 | globenewswire.com
Immutep to Participate in Two Upcoming Investor Conferences - GlobeNewswire
September 26, 2022 | finance.yahoo.com
Immutep to Participate in Two Upcoming Investor Conferences
September 23, 2022 | marketscreener.com
Immutep Gets $1.8 Million Research and Development Incentive from France - Marketscreener.com
See More Headlines

IMMP Price History

IMMP Company Calendar

Today
6/01/2023
Fiscal Year End
6/30/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMMP
CUSIP
N/A
CIK
1506184
Web
www.immutep.com
Phone
(128) 315-7003
Fax
61-2-8569-1880
Employees
2,021
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+397.5%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
8.97
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$4.90 million
Price / Sales
36.07
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.79 per share
Price / Book
2.54

Miscellaneous

Outstanding Shares
87,930,000
Free Float
85,231,000
Market Cap
$176.74 million
Optionable
Not Optionable
Beta
2.39

Key Executives

  • Marc Voigt
    Chief Executive Officer, CFO & Executive Director
  • Deanne Miller
    COO, Secretary & General Counsel
  • David Fang
    Finance Director & Assistant Secretary
  • Florian D. Vogl
    Chief Medical Officer
  • Christian Mueller
    Vice President-Strategic Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













IMMP Stock - Frequently Asked Questions

What is Immutep's stock price forecast for 2023?

0 equities research analysts have issued twelve-month price targets for Immutep's shares. Their IMMP share price forecasts range from $10.00 to $10.00. On average, they expect the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 397.5% from the stock's current price.
View analysts price targets for IMMP or view top-rated stocks among Wall Street analysts.

How have IMMP shares performed in 2023?

Immutep's stock was trading at $1.75 on January 1st, 2023. Since then, IMMP shares have increased by 14.9% and is now trading at $2.01.
View the best growth stocks for 2023 here.

What other stocks do shareholders of Immutep own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immutep investors own include Nuwellis (CHFS), MEI Pharma (MEIP), VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), Gilead Sciences (GILD), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Vascular Biogenics (VBLT).

What is Immutep's stock symbol?

Immutep trades on the NASDAQ under the ticker symbol "IMMP."

Who are Immutep's major shareholders?

Immutep's stock is owned by a variety of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (0.09%), Susquehanna International Group LLP (0.00%), Group One Trading L.P. (0.00%) and Simplex Trading LLC (0.00%).

How do I buy shares of Immutep?

Shares of IMMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immutep's stock price today?

One share of IMMP stock can currently be purchased for approximately $2.01.

How much money does Immutep make?

Immutep (NASDAQ:IMMP) has a market capitalization of $176.74 million and generates $4.90 million in revenue each year.

How many employees does Immutep have?

The company employs 2,021 workers across the globe.

How can I contact Immutep?

Immutep's mailing address is LEVEL 12 95 PITT STREET, SYDNEY C3, 2000. The official website for the company is www.immutep.com. The biotechnology company can be reached via phone at (128) 315-7003, via email at jay.campbell@immutep.com, or via fax at 61-2-8569-1880.

This page (NASDAQ:IMMP) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -